KBC Group’s Arcus Biosciences RCUS Stock Holding History

KBC Group’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$60K	Hold	2,334	–	–	﹤0.01%	1665
2026 Q2	$72K	Hold	2,334	–	–	﹤0.01%	1577
2026 Q1	$50K	Buy	+2,334	New	+$50.4K	﹤0.01%	1654
2024 Q2	–	Sell	-1,952	Closed	-$37K	–	1904
2024 Q1	$37K	Hold	1,952	–	–	﹤0.01%	1698
2023 Q4	$37K	Hold	1,952	–	–	﹤0.01%	1712
2023 Q3	$35K	Sell	1,952 -2,076	-52%	-$41.7K	﹤0.01%	1715
2023 Q2	$82K	Hold	4,028	–	–	﹤0.01%	1243
2023 Q1	$73K	Hold	4,028	–	–	﹤0.01%	1297
2022 Q4	$83K	Hold	4,028	–	–	﹤0.01%	1269
2022 Q3	$105K	Hold	4,028	–	–	﹤0.01%	1166
2022 Q2	$102K	Buy	+4,028	New	+$98.6K	﹤0.01%	1214

Other funds holding RCUS

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return

Parallel Advisors San Francisco, California $7.42B AUM 27.68% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.56B AUM 41.43% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

KBC Group's RCUS Position: Q3 2026 in Review

KBC Group held its Arcus Biosciences (RCUS) position steady in Q3 2026 at 2,334 shares worth $60K. The position accounts for ﹤0.01% of the portfolio, ranked #1665.

KBC Group first reported a position in RCUS in Q2 2022 and has held it in 11 quarters since. The position peaked at $105K in Q3 2022. 63 funds tracked by Wall St. Rank hold RCUS as of Q3 2026.

KBC Group held 2,334 shares of Arcus Biosciences worth $60K as of Q3 2026.
KBC Group left its Arcus Biosciences share count unchanged in Q3 2026.
Arcus Biosciences made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #1665 holding.
KBC Group first reported a position in Arcus Biosciences in Q2 2022 and has held it in 11 quarters since.
KBC Group's Arcus Biosciences position peaked at $105K in Q3 2022.
63 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.